Michael S Leapman1, Stephen J Freedland2, William J Aronson3, Christopher J Kane4, Martha K Terris5, Kelly Walker6, Christopher L Amling7, Peter R Carroll6, Matthew R Cooperberg8. 1. Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California. Electronic address: michael.leapman@yale.edu. 2. Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California. 3. Department of Urology, University of California-Los Angeles Medical Center, Los Angeles, California. 4. Department of Urology, University of California-San Diego Health System, San Diego, California. 5. Department of Urology, Georgia Regents Health System, Augusta, Georgia. 6. Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California. 7. Department of Urology, Oregon Health and Science University, Portland, Oregon. 8. Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California.
Abstract
PURPOSE: Racial disparities in the incidence and risk profile of prostate cancer at diagnosis among African-American men are well reported. However, it remains unclear whether African-American race is independently associated with adverse outcomes in men with clinical low risk disease. MATERIALS AND METHODS: We retrospectively analyzed the records of 895 men in the SEARCH (Shared Equal Access Regional Cancer Hospital) database in whom clinical low risk prostate cancer was treated with radical prostatectomy. Associations of African-American and Caucasian race with pathological biochemical recurrence outcomes were examined using chi-square, logistic regression, log rank and Cox proportional hazards analyses. RESULTS: We identified 355 African-American and 540 Caucasian men with low risk tumors in the SEARCH cohort who were followed a median of 6.3 years. Following adjustment for relevant covariates African-American race was not significantly associated with pathological upgrading (OR 1.33, p = 0.12), major upgrading (OR 0.58, p = 0.10), up-staging (OR 1.09, p = 0.73) or positive surgical margins (OR 1.04, p = 0.81). Five-year recurrence-free survival rates were 73.4% in African-American men and 78.4% in Caucasian men (log rank p = 0.18). In a Cox proportional hazards analysis model African-American race was not significantly associated with biochemical recurrence (HR 1.11, p = 0.52). CONCLUSIONS: In a cohort of patients at clinical low risk who were treated with prostatectomy in an equal access health system with a high representation of African-American men we observed no significant differences in the rates of pathological upgrading, up-staging or biochemical recurrence. These data support continued use of active surveillance in African-American men. Upgrading and up-staging remain concerning possibilities for all men regardless of race.
PURPOSE: Racial disparities in the incidence and risk profile of prostate cancer at diagnosis among African-American men are well reported. However, it remains unclear whether African-American race is independently associated with adverse outcomes in men with clinical low risk disease. MATERIALS AND METHODS: We retrospectively analyzed the records of 895 men in the SEARCH (Shared Equal Access Regional Cancer Hospital) database in whom clinical low risk prostate cancer was treated with radical prostatectomy. Associations of African-American and Caucasian race with pathological biochemical recurrence outcomes were examined using chi-square, logistic regression, log rank and Cox proportional hazards analyses. RESULTS: We identified 355 African-American and 540 Caucasian men with low risk tumors in the SEARCH cohort who were followed a median of 6.3 years. Following adjustment for relevant covariates African-American race was not significantly associated with pathological upgrading (OR 1.33, p = 0.12), major upgrading (OR 0.58, p = 0.10), up-staging (OR 1.09, p = 0.73) or positive surgical margins (OR 1.04, p = 0.81). Five-year recurrence-free survival rates were 73.4% in African-American men and 78.4% in Caucasian men (log rank p = 0.18). In a Cox proportional hazards analysis model African-American race was not significantly associated with biochemical recurrence (HR 1.11, p = 0.52). CONCLUSIONS: In a cohort of patients at clinical low risk who were treated with prostatectomy in an equal access health system with a high representation of African-American men we observed no significant differences in the rates of pathological upgrading, up-staging or biochemical recurrence. These data support continued use of active surveillance in African-American men. Upgrading and up-staging remain concerning possibilities for all men regardless of race.
Authors: Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund Journal: Eur Urol Date: 2012-02-24 Impact factor: 20.096
Authors: Debasish Sundi; Farzana A Faisal; Bruce J Trock; Patricia K Landis; Zhaoyong Feng; Ashley E Ross; H Ballentine Carter; Edward M Schaeffer Journal: Urology Date: 2014-10-14 Impact factor: 2.649
Authors: M Tsivian; L L Bañez; C J Keto; M R Abern; P Qi; L Gerber; J W Moul; T J Polascik Journal: Prostate Cancer Prostatic Dis Date: 2012-10-02 Impact factor: 5.554
Authors: Brian D Odom; M C Mir; Scott Hughes; Cedric Senechal; Alexis Santy; Remi Eyraud; Andrew J Stephenson; Kelly Ylitalo; Ranko Miocinovic Journal: Urology Date: 2013-11-26 Impact factor: 2.649
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Alexis R Gaines; Elizabeth L Turner; Patricia G Moorman; Stephen J Freedland; Christopher J Keto; Megan E McPhail; Delores J Grant; Adriana C Vidal; Cathrine Hoyo Journal: Cancer Causes Control Date: 2014-05-31 Impact factor: 2.506
Authors: Chad R Ritch; Belinda F Morrison; Greg Hruby; Kathleen C Coard; Richard Mayhew; William Aiken; Mitchell C Benson; James M McKiernan Journal: BJU Int Date: 2012-10-26 Impact factor: 5.588
Authors: Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan Journal: Cancer Date: 2006-03-15 Impact factor: 6.860
Authors: Yun-Sok Ha; Amirali Salmasi; Michael Karellas; Eric A Singer; Jeong Hyun Kim; Misop Han; Alan W Partin; Wun-Jae Kim; Dong Hyeon Lee; Isaac Yi Kim Journal: Urology Date: 2013-03-07 Impact factor: 2.649
Authors: Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis Journal: Int Urol Nephrol Date: 2019-03-06 Impact factor: 2.370
Authors: J Kellogg Parsons; John P Pierce; James Mohler; Electra Paskett; Sin-Ho Jung; Michael J Morris; Eric Small; Olwen Hahn; Peter Humphrey; John Taylor; James Marshall Journal: BJU Int Date: 2017-05-21 Impact factor: 5.588
Authors: Hari T Vigneswaran; Luke Mittelstaedt; Alessio Crippa; Martin Eklund; Adriana Vidal; Stephen J Freedland; Michael R Abern Journal: Prostate Cancer Prostatic Dis Date: 2021-07-08 Impact factor: 5.554
Authors: Tyler J Nelson; Juan Javier-DesLoges; Rishi Deka; P Travis Courtney; Vinit Nalawade; Loren Mell; James Murphy; J Kellogg Parsons; Brent S Rose Journal: JAMA Netw Open Date: 2021-05-03
Authors: Jonathan B Bloom; Amir H Lebastchi; Samuel A Gold; Graham R Hale; Thomas Sanford; Sherif Mehralivand; Michael Ahdoot; Kareem N Rayn; Marcin Czarniecki; Clayton Smith; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto Journal: BJU Int Date: 2019-06-26 Impact factor: 5.969
Authors: Jeannette M Schenk; Lisa F Newcomb; Yingye Zheng; Anna V Faino; Kehao Zhu; Yaw A Nyame; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; Christopher P Filson; Martin E Gleave; Michael Liss; Francis M Martin; Todd M Morgan; Peter S Nelson; Ian M Thompson; Andrew A Wagner; Daniel W Lin Journal: J Urol Date: 2019-10-25 Impact factor: 7.450